Hemopoietic stem cell processing: comparison of progenitor cell recovery using the Cobe 2991 cell washer and the Haemonetics V50 apheresis system.

abstract：:When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early a...

journal_title：Bone marrow transplantation

authors： Johnson BD,Drobyski WR,Truitt RL

更新日期：1993-04-01 00:00:00

abstract：:To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

journal_title：Bone marrow transplantation

authors： Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

更新日期：1988-01-01 00:00:00

abstract：:Bone marrow aspirates are composed of two cellular compartments, an abundant buffy coat suspension and a minor particulate fraction. The particulate fraction is routinely removed by filtration prior to transplantation in order to reduce the risk of embolism. This study shows that the filter-retained fraction includes ...

journal_title：Bone marrow transplantation

authors： Blazsek I,Delmas Marsalet B,Legras S,Marion S,Machover D,Misset JL

更新日期：1999-04-01 00:00:00

abstract：:Hypophosphatemia associated with bone marrow transplantation has been infrequently reported. The suggested mechanism is phosphate uptake by the replicating cells. Various cytokines are associated with the development of hypophosphatemia. The present study evaluated the interrelationship between cytokine release, the r...

journal_title：Bone marrow transplantation

authors： Raanani P,Levi I,Holzman F,Grotto I,Brok-Simoni F,Avigdor A,Davidson J,Shpilberg O,Ben-Bassat I

更新日期：2001-02-01 00:00:00

abstract：:The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilizat...

journal_title：Bone marrow transplantation

authors： Goterris R,Hernández-Boluda JC,Teruel A,Gómez C,Lis MJ,Terol MJ,Tormo M,Solano C,Arbona C

更新日期：2005-11-01 00:00:00

abstract：:A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

journal_title：Bone marrow transplantation

authors： Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

更新日期：2004-01-01 00:00:00

abstract：:Patients undergoing bone marrow transplantation are profoundly immunosuppressed as a result of their intensive myeloablative chemotherapy and are at high risk for opportunistic fungal infections mainly caused by Candida spp and Aspergillus spp. Trichosporon beigelii (T beigelii) has emerged as a life-threatening oppor...

journal_title：Bone marrow transplantation

authors： Erer B,Galimberti M,Lucarelli G,Giardini C,Polchi P,Baronciani D,Gaziev D,Angelucci E,Izzi G

更新日期：2000-04-01 00:00:00

abstract：:We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer. Five patients responded ...

journal_title：Bone marrow transplantation

authors： Woo MH,Ippoliti C,Bruton J,Mehra R,Champlin R,Przepiorka D

更新日期：1997-04-01 00:00:00

abstract：:Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

journal_title：Bone marrow transplantation

authors： Holtan SG,MacMillan ML

更新日期：2016-02-01 00:00:00

abstract：:In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

journal_title：Bone marrow transplantation

authors： Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

更新日期：2014-12-01 00:00:00

abstract：:Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

journal_title：Bone marrow transplantation

authors： Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

更新日期：2003-08-01 00:00:00

abstract：:We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity condi...

journal_title：Bone marrow transplantation

authors： Bregni M,Fleischhauer K,Bernardi M,Pescarollo A,Guggiari E,Lunghi F,Deola S,Scaramuzza S,Re F,Setola E,Monari M,Mazzi B,Servida P,Corradini P,Peccatori J

更新日期：2006-02-01 00:00:00

abstract：:We have retrospectively analyzed the impact of prognostic factors on the outcome of serologically HLA-matched unrelated donor (UD) BMT for CML. For this purpose, we have studied a cohort of 366 patients transplanted in Europe between January 1985 and December 1994. The median age of the 211 males and 155 females was 3...

journal_title：Bone marrow transplantation

authors： Devergie A,Apperley JF,Labopin M,Madrigal A,Jacobsen N,Carreras E,Prentice HG,Jouet JP,Kolb HJ,Herstenstein B,Bacigalupo A,Evensen SA,Ljungman P,de Witte T,Reiffers J,Nagler A,Clark RE,Goldman JM,Gratwohl A

更新日期：1997-07-01 00:00:00

abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

journal_title：Bone marrow transplantation

authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

更新日期：2015-06-01 00:00:00

abstract：:The pharmacokinetics of tacrolimus following its administration as monotherapy or in combination with corticosteroids or methotrexate to 31 BMT patients are presented. All patients received i.v. tacrolimus initially and were subsequently switched to p.o. dosing. Patients received methotrexate by i.v. bolus on post-tra...

journal_title：Bone marrow transplantation

authors： Boswell GW,Bekersky I,Fay J,Wingard J,Antin J,Weisdorf D,Maher R,Fitzsimmons W,Nash R

更新日期：1998-01-01 00:00:00

abstract：:Syngeneic BMT was first performed successfully in China in 1964. In 1981, allogeneic BMT was applied in an acute leukemia patient with success. Since then, the number of BMTs has been increasing gradually, especially since the 1990s. More than 2000 stem cell transplants per year have been performed in recent years in ...

journal_title：Bone marrow transplantation

authors： Wu T,Lu DP

更新日期：2008-08-01 00:00:00

abstract：:The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

journal_title：Bone marrow transplantation

authors： Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

更新日期：2012-02-01 00:00:00

abstract：:The purpose of this study was to measure the trajectory of psychosocial recovery over the first year after bone marrow transplantation (BMT). BMT patients were assessed at baseline (n = 86), hospital discharge (n = 74), 100 days (n = 64) and at 1 year (n = 45). Participants completed the Functional Assessment of Cance...

journal_title：Bone marrow transplantation

authors： McQuellon RP,Russell GB,Rambo TD,Craven BL,Radford J,Perry JJ,Cruz J,Hurd DD

更新日期：1998-03-01 00:00:00

abstract：:The effectiveness of an antibody-enzyme immunotoxin (eIT) was investigated on human T cells. This enzyme immunotoxin contained glucose oxidase (GO) and lactoperoxidase (LPO) chemically coupled to the pan-leukocyte-specific mouse monoclonal antibody (MoAb) 097 (097-GO and 097-LPO). Human peripheral blood mononuclear ce...

journal_title：Bone marrow transplantation

authors： Ito HO,Morizet J,Coulombel L,Goavec M,Rousseau V,Bernard A,Stanislawski M

更新日期：1989-09-01 00:00:00

abstract：:To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etop...

journal_title：Bone marrow transplantation

authors： Kröger N,Zabelina T,Sonnenberg S,Krüger W,Renges H,Stute N,Finkenstein F,Mayer U,Holstein K,Fiedler W,Colberg H,Sonnen R,Kuse R,Braumann D,Metzner B,del Valle F,Erttmann R,Kabisch H,Zander AR

更新日期：2000-10-01 00:00:00

abstract：:We report a 5-year-old boy with juvenile myelomonocytic leukemia (JMML) which relapsed after an allogeneic bone marrow transplant who was successfully treated with interferon-alpha (IFN-alpha). One year after starting the therapy, he remains clinically well and in complete remission while continuing treatment with IFN...

journal_title：Bone marrow transplantation

authors： Ohta H,Kawai M,Sawada A,Tokimasa S,Fujisaki H,Matsuda Y,Osugi Y,Okada S,Hara J

更新日期：2000-09-01 00:00:00

abstract：:Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 concentration, is necessary to obtain a maximal pharmacological effect and correlates well with transplant-related complications such as transplant rejection and toxicity. In an open crossover study CsA blood levels were mea...

journal_title：Bone marrow transplantation

authors： Hendriks MP,Blijlevens NM,Schattenberg AV,Burger DM,Donnelly JP

更新日期：2006-10-01 00:00:00

abstract：:Among 42 consecutive recipients of unrelated marrow were 39 HLA-A, -B, -DR identical, matched unrelated donors (MUD) and three with one HLA antigen mismatch. The majority were genomically typed for DRB, DQA, DQB and DPB. The recipients of MUD marrow were compared with 39 recipients of marrow from HLA-identical sibling...

journal_title：Bone marrow transplantation

authors： Ringdén O,Remberger M,Persson U,Ljungman P,Aldener A,Andström E,Aschan J,Bolme P,Dahllöf G,Dalianis T

更新日期：1995-04-01 00:00:00

abstract：:Umbilical cord blood (UCB) is a readily available source of hematopoietic stem cells for transplantation. UCB hematopoietic SCT for average- and large-sized patients is often limited by the number of cells available in a single unit. To address this limitation, we performed experiments to determine if adjunctive thera...

journal_title：Bone marrow transplantation

authors： Budak-Alpdogan T,Jeganathan G,Lee KC,Mrowiec ZR,Medina DJ,Todd D,Moore D,Bertino JR,Strair R

更新日期：2012-12-01 00:00:00

abstract：:We conducted an observational study to assess the etiology, clinical features and outcomes of bloodstream infection (BSI) in 172 hematopoietic SCT (HCST) recipients. One hundred episodes of BSI in the pre-engraftment period (early onset) were compared with 89 episodes in the post-engraftment phase (late onset). More p...

journal_title：Bone marrow transplantation

authors： Gudiol C,Garcia-Vidal C,Arnan M,Sánchez-Ortega I,Patiño B,Duarte R,Carratalà J

更新日期：2014-06-01 00:00:00

abstract：:Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TA...

journal_title：Bone marrow transplantation

authors： Labrador J,López-Corral L,López-Godino O,Vázquez L,Cabrero-Calvo M,Pérez-López R,Díez-Campelo M,Sánchez-Guijo F,Pérez-López E,Guerrero C,Alberca I,Del Cañizo MC,Pérez-Simón JA,González-Porras JR,Caballero D

更新日期：2014-05-01 00:00:00

abstract：:Thrombotic microangiopathy (TM) is a serious complication of bone marrow transplantation (BMT) that resembles thrombotic thrombocytopenic purpura (TTP). In attempting to achieve hematopoietic cell chimerism in the pig-to-baboon model, we have observed TM following infusion of high doses (>10(10) cells/kg) of porcine p...

journal_title：Bone marrow transplantation

authors： Bühler L,Goepfert C,Kitamura H,Basker M,Gojo S,Alwayn IP,Chang Q,Down JD,Tsai H,Wise R,Sachs DH,Cooper DK,Robson SC,Sackstein R

更新日期：2001-06-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) may be the only curative option for some older adults with hematologic malignancies, and its associated risks of significant morbidity and mortality warrant a clear, informed decision-making process. As older adults have not been transplanted routinely until rece...

journal_title：Bone marrow transplantation

authors： Randall J,Keven K,Atli T,Ustun C

更新日期：2016-05-01 00:00:00

abstract：:Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot study evaluating the topical vitamin D3 analog Calcipotriene (DOVONEX 0.005% cream) for acute skin GVHD i...

journal_title：Bone marrow transplantation

authors： Wallace G,Khandelwal P,Myers KC,Perentesis EMR,Lane A,Teusink-Cross A,Smiley K,Davies SM,Jodele S

更新日期：2021-01-08 00:00:00

abstract：:Comprehensive programmes for BMT started in Hong Kong in 1990. As of September 1993, there are a total of 13 BMT beds in Government-funded University Hospitals performing about 110 transplants per year or 18 transplants per million population per year. So far, 194 transplants were performed: allogeneic BMT (72.2%), au...

journal_title：Bone marrow transplantation

authors： Chiu EK,Yuen P,Chan TK

更新日期：1994-06-01 00:00:00